Utilizing proteomics to understand and define hypertension: where are we and where do we go?

References

• De Hert S. Physiology of hemodynamic homeostasis. Best Pract Res Clin Anaesthesiol. 2012;26(4):409–419.
   PubMedGoogle Scholar
• Singh M, Mensah GA, Bakris G. Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 2010;28(4):545–559.
   PubMed Web of Science ®Google Scholar
• Aubiniere-Robb L, Jeemon P, Hastie CE, et al. Blood pressure response to patterns of weather fluctuations and effect on mortality. Hypertension. 2013;62(1):190–196.
   PubMed Web of Science ®Google Scholar
• Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res. 2015;116(6):1034–1045.
   PubMed Web of Science ®Google Scholar
• Moser M. Historical perspectives on the management of hypertension. J Clin Hypertens (Greenwich). 2006;8(8 Suppl 2):15–20.
   PubMedGoogle Scholar
• Franklin SS, Wong ND. Hypertension and cardiovascular disease: contributions of the framingham heart study. Glob Heart. 2013;8(1):49–57.
   PubMedGoogle Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Clinical Guidance 127. [cited 2018 Jun 4 Available from: https://www.nice.org.uk/guidance/cg127
   Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2017;71(6):e13–e115.
   PubMed Web of Science ®Google Scholar
• SPRINT Research Group, Wright JT, Jr., Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373(22):2103–2116.
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913.
   PubMed Web of Science ®Google Scholar
• Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension. Circ Res. 2015;116(6):937–959.
   PubMed Web of Science ®Google Scholar
• Lawes CM, Vander Hoorn S, Rodgers A, et al. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513–1518.
   PubMed Web of Science ®Google Scholar
• Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–450.
   PubMed Web of Science ®Google Scholar
• Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet commission on hypertension. Lancet. 2016;388(10060):2665–2712.
   PubMed Web of Science ®Google Scholar
• GBD. 2013 mortality and causes of death collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385(9963):117–171.
   PubMed Web of Science ®Google Scholar
• Lindsey ML, Mayr M, Gomes AV, et al. Transformative impact of proteomics on cardiovascular health and disease: a scientific statement from the American Heart Association. Circulation. 2015;132(9):852–872.
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Pasquali C, Appel RD, et al. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (N Y). 1996;14(1):61–65.
   PubMedGoogle Scholar
• You S-A, Wang QK. Proteomics with two-dimensional gel electrophoresis and mass spectrometry analysis in cardiovascular research. In: Wang QK, ed. Cardiovascular disease: methods and protocols volume 2: molecular medicine. Totowa, NJ: Humana Press; 2007. p. 15–26.
   Google Scholar
• Evans G, Wheeler C, Corbett J, et al. Construction of HSC-2DPAGE: a two-dimensional gel electrophoresis database of heart proteins. Electrophoresis. 1997;18(3–4):471–479.
   PubMed Web of Science ®Google Scholar
• Wilm MS, Mann M. Electrospray and Taylor-Cone theory, Dole’s beam of macromolecules at last? Int J Mass Spectrom Ion Process. 1994;136(2):167–180.
   Web of Science ®Google Scholar
• Wisniewski JR, Zougman A, Nagaraj N, et al. Universal sample preparation method for proteome analysis. Nat Meth. 2009;6(5):359–362.
   PubMed Web of Science ®Google Scholar
• Albalat A, Mullen W, Husi H, et al. Tissue proteomics in vascular disease. In: Touyz RM, Schiffrin EL eds. Hypertension: methods and protocols. New York, NY: Springer New York; 2017. p. 53–60.
   Google Scholar
• Makarov A, Denisov E, Kholomeev A, et al. Performance evaluation of a hybrid linear ion trap/Orbitrap mass spectrometer. Anal Chem. 2006;78(7):2113–2120.
   PubMed Web of Science ®Google Scholar
• Boja ES, Rodriguez H. Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. Proteomics. 2012;12(8):1093–1110.
   PubMed Web of Science ®Google Scholar
• Chang C-T, Yang C-Y, Tsai F-J, et al. Mass spectrometry-based proteomic study makes high-density lipoprotein a biomarker for atherosclerotic vascular disease. BioMed Res Int. 2015;2015:13.
   Google Scholar
• Cui L, Nithipatikom K, Campbell WB. Simultaneous analysis of angiotensin peptides by LC-MS and LC-MS/MS: metabolism by bovine adrenal endothelial cells. Anal Biochem. 2007;369(1):27–33.
   PubMed Web of Science ®Google Scholar
• Delles C, Schiffer E, von Zur Muhlen C et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens. 2010;28(11):2316–2322.
   PubMed Web of Science ®Google Scholar
• Neisius U, Koeck T, Mischak H, et al. Urine proteomics in the diagnosis of stable angina. BMC Cardiovasc Disord. 2016;16:70.
   PubMed Web of Science ®Google Scholar
• Terzi F, Cambridge S. An overview of advanced SILAC-labeling strategies for quantitative proteomics. Methods Enzymol. 2017;585:29–47.
   PubMed Web of Science ®Google Scholar
• Delles C, Neisius U, Carty DM. Proteomics in hypertension and other cardiovascular diseases. Ann Med. 2012;44(Suppl 1):S55–S64.
   PubMedGoogle Scholar
• Goldblatt H. Studies on experimental hypertension, V: the pathogenesis of experimental hypertension due to renal ischemia. Ann Intern Med. 1937;11:69–103.
   Google Scholar
• Kim S, Tokuyama M, Hosoi M, et al. Adrenal and circulating renin-angiotensin system in stroke-prone hypertensive rats. Hypertension. 1992;20(3):280–291.
   PubMed Web of Science ®Google Scholar
• Skeggs LT Jr., Kahn JR, Shumway NP. The preparation and function of the hypertensin-converting enzyme. J Exp Med. 1956;103(3):295–299.
   PubMed Web of Science ®Google Scholar
• Kim S, Ohta K, Hamaguchi A, et al. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension. 1995;25(6):1252–1259.
   PubMed Web of Science ®Google Scholar
• Schorb W, Booz GW, Dostal DE, et al. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res. 1993;72(6):1245–1254.
   PubMed Web of Science ®Google Scholar
• Simon G, Abraham G, Cserep G. Pressor and subpressor angiotensin II administration. Two experimental models of hypertension. Am J Hypertens. 1995;8(6):645–650.
   PubMed Web of Science ®Google Scholar
• Kawada N, Imai E, Karber A, et al. A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol. 2002;13(12):2860–2868.
   PubMed Web of Science ®Google Scholar
• Li XC, Zhuo JL. Phosphoproteomic analysis of AT1 receptor-mediated signaling responses in proximal tubules of angiotensin II-induced hypertensive rats. Kidney Int. 2011;80(6):620–632.
   PubMed Web of Science ®Google Scholar
• Brooks HL, Allred AJ, Beutler KT, et al. Targeted proteomic profiling of renal Na(+) transporter and channel abundances in angiotensin II type 1a receptor knockout mice. Hypertension. 2002;39(2 Pt 2):470–473.
   PubMed Web of Science ®Google Scholar
• Gebhard S, Steil L, Peters B, et al. Angiotensin II-dependent hypertension causes reversible changes in the platelet proteome. J Hypertens. 2011;29(11):2126–2137.
   PubMed Web of Science ®Google Scholar
• Ayyadevara S, Mercanti F, Wang X, et al. Age- and hypertension-associated protein aggregates in mouse heart have similar proteomic profiles. Hypertension. 2016;67(5):1006–1013.
   PubMed Web of Science ®Google Scholar
• Finckenberg P, Eriksson O, Baumann M, et al. Caloric restriction ameliorates angiotensin II-induced mitochondrial remodeling and cardiac hypertrophy. Hypertension. 2012;59(1):76–84.
   PubMed Web of Science ®Google Scholar
• Gao BB, Stuart L, Feener EP. Label-free quantitative analysis of one-dimensional PAGE LC/MS/MS proteome: application on angiotensin II-stimulated smooth muscle cells secretome. Mol Cell Proteomics. 2008;7(12):2399–2409.
   PubMed Web of Science ®Google Scholar
• McKinney CA, Fattah C, Loughrey CM, et al. Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. Clin Sci (Lond). 2014;126(12):815–827.
   PubMed Web of Science ®Google Scholar
• Verano-Braga T, Schwammle V, Sylvester M, et al. Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res. 2012;11(6):3370–3381.
   PubMed Web of Science ®Google Scholar
• Wang HJ, Chen SF, Lo WY. Identification of cofilin-1 induces G0/G1 arrest and autophagy in angiotensin-(1-7)-treated human aortic endothelial cells from iTRAQ quantitative proteomics. Sci Rep. 2016;6:35372.
   PubMed Web of Science ®Google Scholar
• Bamburg JR, McGough A, Ono S. Putting a new twist on actin: ADF/cofilins modulate actin dynamics. Trends Cell Biol. 1999;9(9):364–370.
   PubMed Web of Science ®Google Scholar
• Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer. 2007;7(6):429–440.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J. 1963;27:282–293.
   PubMedGoogle Scholar
• Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res. 1998;39(1):89–105.
   PubMed Web of Science ®Google Scholar
• Koh-Tan HH, Dashti M, Wang T, et al. Dissecting the genetic components of a quantitative trait locus for blood pressure and renal pathology on rat chromosome 3. J Hypertens. 2017;35(2):319–329.
   PubMed Web of Science ®Google Scholar
• Nabika T, Ohara H, Kato N, et al. The stroke-prone spontaneously hypertensive rat: still a useful model for post-GWAS genetic studies? Hypertens Res. 2012;35(5):477–484.
   PubMed Web of Science ®Google Scholar
• Atanur SS, Birol I, Guryev V, et al. The genome sequence of the spontaneously hypertensive rat: analysis and functional significance. Genome Res. 2010;20(6):791–803.
   PubMed Web of Science ®Google Scholar
• Hubner N, Wallace CA, Zimdahl H, et al. Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. Nat Genet. 2005;37(3):243–253.
   PubMed Web of Science ®Google Scholar
• Pravenec M, Kurtz TW. Recent advances in genetics of the spontaneously hypertensive rat. Curr Hypertens Rep. 2010;12(1):5–9.
   PubMed Web of Science ®Google Scholar
• Jin X, Xia L, Wang LS, et al. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics. 2006;6(6):1948–1956.
   PubMed Web of Science ®Google Scholar
• Lee CK, Han JS, Won KJ, et al. Diminished expression of dihydropteridine reductase is a potent biomarker for hypertensive vessels. Proteomics. 2009;9(21):4851–4858.
   PubMed Web of Science ®Google Scholar
• Bendall JK, Douglas G, McNeill E, et al. Tetrahydrobiopterin in cardiovascular health and disease. Antioxid Redox Signal. 2014;20(18):3040–3077.
   PubMed Web of Science ®Google Scholar
• Hatziioanou D, Barkas G, Critselis E, et al. Chloride intracellular channel 4 overexpression in the proximal tubules of kidneys from the spontaneously hypertensive rat: insight from proteomic analysis. Nephron. 2018;138(1):60–70.
   PubMed Web of Science ®Google Scholar
• Feng H, Li H, Zhang D, et al. Aortic wall proteomic analysis in spontaneously hypertensive rats with a blood pressure decrease induced by 6-week load-free swimming. Biomed Rep. 2015;3(5):681–686.
   PubMed Web of Science ®Google Scholar
• Low TY, van Heesch S, van den Toorn H, et al. Quantitative and qualitative proteome characteristics extracted from in-depth integrated genomics and proteomics analysis. Cell Rep. 2013;5(5):1469–1478.
   PubMed Web of Science ®Google Scholar
• Manakov D, Ujcikova H, Pravenec M, et al. Alterations in the cardiac proteome of the spontaneously hypertensive rat induced by transgenic expression of CD36. J Proteomics. 2016;145:177–186.
   PubMed Web of Science ®Google Scholar
• Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44(4):398–404.
   PubMed Web of Science ®Google Scholar
• Carty DM, Schiffer E, Delles C. Proteomics in hypertension. J Hum Hypertens. 2013;27(4):211–216.
   PubMed Web of Science ®Google Scholar
• Currie G, Delles C. The future of “omics” in hypertension. Can J Cardiol. 2017;33(5):601–610.
   PubMed Web of Science ®Google Scholar
• Argiles A, Rodriguez M, Ortiz A. Is plasma proteomics able to provide alternative paths to better understand hypertension? Hypertension. 2017;70(2):250–252.
   PubMed Web of Science ®Google Scholar
• Gajjala PR, Jankowski V, Heinze G, et al. Proteomic-biostatistic integrated approach for finding the underlying molecular determinants of hypertension in human plasma. Hypertension. 2017;70(2):412–419.
   PubMed Web of Science ®Google Scholar
• Matafora V, Zagato L, Ferrandi M, et al. Quantitative proteomics reveals novel therapeutic and diagnostic markers in hypertension. BBA Clin. 2014;2:79–87.
   PubMedGoogle Scholar
• Johansson M, Ricci F, Aung N, et al. Proteomic profiling for cardiovascular biomarker discovery in orthostatic hypotension. Hypertension. 2018;71(3):465–472.
   PubMed Web of Science ®Google Scholar
• Kuznetsova T, Mischak H, Mullen W, et al. Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. Eur Heart J. 2012;33(18):2342–2350.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Staessen JA, Thijs L, et al. Left ventricular diastolic function in relation to the urinary proteome: a proof-of-concept study in a general population. Int J Cardiol. 2014;176(1):158–165.
   PubMed Web of Science ®Google Scholar
• Brown CE, McCarthy NS, Hughes AD, et al. Urinary proteomic biomarkers to predict cardiovascular events. Proteomics Clin Appl. 2015;9(5–6):610–617.
   PubMed Web of Science ®Google Scholar
• Petriz BA, Franco OL. Effects of hypertension and exercise on cardiac proteome remodelling. Biomed Res Int. 2014;2014:634132.
   PubMedGoogle Scholar
• Pena MJ, Jankowski J, Heinze G, et al. Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. J Hypertens. 2015;33(10):2123–2132.
   PubMed Web of Science ®Google Scholar
• Baldan-Martin M, Mourino-Alvarez L, Gonzalez-Calero L, et al. Plasma molecular signatures in hypertensive patients with renin-angiotensin system suppression: new predictors of renal damage and de novo albuminuria indicators. Hypertension. 2016;68(1):157–166.
   PubMed Web of Science ®Google Scholar
• Martin-Lorenzo M, Gonzalez-Calero L, Martinez PJ, et al. Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria. Sci Rep. 2017;7(1):8894.
   PubMedGoogle Scholar
• Gonzalez-Calero L, Martinez PJ, Martin-Lorenzo M, et al. Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria. Oncotarget. 2017;8(27):44217–44231.
   PubMedGoogle Scholar
• Zhang W, Chen X, Yan Z, et al. Detergent-insoluble proteome analysis revealed aberrantly aggregated proteins in human preeclampsia placentas. J Proteome Res. 2017;16(12):4468–4480.
   PubMed Web of Science ®Google Scholar
• Jin X, Xu Z, Cao J, et al. Proteomics analysis of human placenta reveals glutathione metabolism dysfunction as the underlying pathogenesis for preeclampsia. Biochim Biophys Acta. 2017;1865(9):1207–1214.
   PubMedGoogle Scholar
• Mary S, Kulkarni MJ, Malakar D, et al. Placental proteomics provides insights into pathophysiology of pre-eclampsia and predicts possible markers in plasma. J Proteome Res. 2017;16(2):1050–1060.
   PubMed Web of Science ®Google Scholar
• Ma K, Jin H, Hu R, et al. A proteomic analysis of placental trophoblastic cells in preeclampsia-eclampsia. Cell Biochem Biophys. 2014;69(2):247–258.
   PubMed Web of Science ®Google Scholar
• Myers JE, Tuytten R, Thomas G, et al. Integrated proteomics pipeline yields novel biomarkers for predicting preeclampsia. Hypertension. 2013;61(6):1281–1288.
   PubMed Web of Science ®Google Scholar
• Chen G, Zhang Y, Jin X, et al. Urinary proteomics analysis for renal injury in hypertensive disorders of pregnancy with iTRAQ labeling and LC-MS/MS. Proteomics Clin Appl. 2011;5(5–6):300–310.
   PubMed Web of Science ®Google Scholar
• Carty DM, Siwy J, Brennand JE, et al. Urinary proteomics for prediction of preeclampsia. Hypertension. 2011;57(3):561–569.
   PubMed Web of Science ®Google Scholar
• Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661–678.
   PubMed Web of Science ®Google Scholar
• Padmanabhan S, Melander O, Johnson T, et al. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet. 2010;6(10):e1001177.
   PubMed Web of Science ®Google Scholar
• Surendran P, Drenos F, Young R, et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat Genet. 2016;48(10):1151–1161.
   PubMed Web of Science ®Google Scholar
• Dominiczak A, Delles C, Padmanabhan S. Genomics and precision medicine for clinicians and scientists in hypertension. Hypertension. 2017;69(4):e10–e13.
   PubMed Web of Science ®Google Scholar
• Buhler FR, Burkart F, Lutold BE, et al. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol. 1975;36(5):653–669.
   PubMed Web of Science ®Google Scholar
• Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–2068.
   PubMed Web of Science ®Google Scholar